Earlier this year, Valeant reportedly turned down a takeover offer from Takeda and TPG. Now, the Japanese drugmaker wants to snag just one piece of the embattled company--and this time, Valeant may be happy to oblige.
Shenzhen-based Hepalink Pharmaceutical has added to its investment TPG Biotechnology Partners with a $60 million pledge for the V fund as it seeks wider business opportunities.
